ICOVIR15-cBiTE

N/A

Report date: 2026/03/19 16:58:14

Base Information

Drug NameICOVIR15-cBiTE
Drug Alias Nameanti-CD3/anti-EGFR bispecific T-cell engager (Theriva Biologics)anti-CD3/anti-EGFR bispecific T-cell engager (VCN Biosciences)anti-CD3/anti-EGFR bispecific T-cell engager (Synthetic Biologics)ICOVIR15-cBiTE-loaded menstrual blood derived-mesenchymal stem cells (VCN Biosciences/Instituto de Salud Carlos III/Instituto Catalan de Oncologia)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Oncolytic virusCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy +[4] 
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpidermal growth factor receptor erbB1 modulators
TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstituto Catalan de Oncologia
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Catalan de OncologiaInstituto de Salud Carlos IIITheriva Biologics Inc
Inactive CompaniesTheriva Biologics SL
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A